Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4939)	7/22/1998 2:21:00 AM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Steve, I took detailed notes on the call ... it was just too tiring to go back to them for my previous post. The argument on the oncology division is as follows: - a number of companies have used these types of separately traded securities to "unlock" the value of disparate assets. PJ posited the street assigns $0 value to the oncology pipeline. He says as a standalone development stage biotech, the cancer business alone would stack up well against other development stage companies targeting that space ... citing ENMD and BBIOY (had to refer back to my notes for that : ) - since AGPH has inlicensed the three HIV products, all of which they are very positive on, R&D spending of course goes up a great deal FY 99 [btw, it was already up due to Roche pulling out late last year]. Pulling the $45M in cancer products R&D lets the Viracept + emerging anti-viral franchise report earnings more in line with their performance. How will this all play on the street? And, how to evaluate this as a strategic move? Not sure yet. Still need to see the prospectus, but that's a few weeks out. Peter